Enzyme studies in tardive dyskinesia. II. Familial aspects. 1982

L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt

Two peripheral enzymes, dopamine-beta-hydroxylase (DBH) and monoamine oxidase (MAO), have previously been found to be altered in patients with tardive dyskinesia (TD). In order to examine whether these changes relate to the inherited component of enzyme activity or environmental factors, we assayed DBH and MAO activities in families of six TD probands and six matched non-TD probands. Five of six TD probands had DBH activity at least 50% greater than that of the family mean, whereas two of six non-TD probands had the same trend. No deviation from family means was suggested for MAO activity in the TD group. A study of chronic schizophrenic quadruplets with a history of prolonged neuroleptic treatment showed that only one quadruplet had TD. This quadruplet had plasma DBH activity four standard deviations above the means for her three siblings and three other family members. Our data do not support inheritance of predisposition to develop TD. The enzymatic alterations in TD patients do not seem to have been determined genetically, but they are probably a result of abnormal biochemical effects of prolonged neuroleptic treatment in those patients.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004299 Dopamine beta-Hydroxylase Dopamine beta-Monooxygenase,Dopamine beta Hydroxylase,Dopamine beta Monooxygenase,beta-Hydroxylase, Dopamine,beta-Monooxygenase, Dopamine
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
December 1981, The American journal of psychiatry,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
June 1976, The St. Luke's Hospital gazette,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
November 2001, Acta psychiatrica Scandinavica,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
April 1981, The Journal of clinical psychiatry,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
September 1988, L'Encephale,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
September 1988, L'Encephale,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
April 1976, Psychopharmacology bulletin,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
October 1982, Journal of clinical psychopharmacology,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
October 1989, International clinical psychopharmacology,
L E Delisi, and D V Jeste, and B H Phelps, and R J Wyatt
October 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Copied contents to your clipboard!